After 14 years, GET AN IND SUBMISSION IN TO THE FDA!!Has this been discussed?
Why has there been no communication from Bioasis regarding the June 25, 2019 PR (excerpt below)?
The Company’s lead program, xB3-001, an xB3 peptide vector trastuzumab fusion, is being readied for clinical testing for the treatment of HER2+ breast cancer brain metastases.
In less than 3 months, it will be 3 years since that press release. How can one not believe something is happening behing the scences? xB3-001 is way too valuable to let it sit.
DrDR knows the clock is ticking.